Current treatment options for familial adult myoclonus epilepsy.
FAME
benzodiazepine
levetiracetam
myoclonus
perampanel
valproate
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
24
02
2023
received:
20
12
2022
accepted:
20
03
2023
medline:
19
6
2023
pubmed:
23
3
2023
entrez:
22
3
2023
Statut:
ppublish
Résumé
Familial adult myoclonus epilepsy (FAME) is a genetic condition characterized by the occurrence of cortical tremor, myoclonus, and epilepsy. To date, there is neither a curative nor a preventive treatment for FAME. Clinical management is essentially symptomatic and based on antiseizure medications (ASMs). The choice of the correct therapeutic option is limited to ASMs that have both an antiseizure and an antimyoclonic effect, such as valproate, levetiracetam, benzodiazepines, and perampanel. However, these medications control seizures well while having a limited effect on myoclonus and cortical tremor. In addition, many ASMs, including sodium channel blockers and gabapentin, are contraindicated in this condition. The ideal therapeutic option would be a precision treatment able to revert the genetic defect underlying it. Nevertheless, this does not seem to be an option that will be available soon.
Substances chimiques
Valproic Acid
614OI1Z5WI
Anticonvulsants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
S58-S63Subventions
Organisme : Università degli Studi di Napoli Federico II
ID : STARPLUS EPIG-033
Informations de copyright
© 2023 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
Ikeda A, Kakigi R, Funai N, Neshige R, Kuroda Y, Shibasaki H. Cortical tremor: a variant of cortical reflex myoclonus. Neurology. 1990;40(10):1561-5.
Latorre A, Rothwell JC. Myoclonus and COVID-19: a challenge for the present, a lesson for the future. Mov Disord Clin Pract. 2020;7(8):888-90.
Uyama E, Fu YH, Ptácek LJ. In: AV GRD-E, Medina MT, Genton P, Bureau M, Dravet C, editors. Familial adult myoclonic epilepsy (FAME), in adv neurol. Philadelphia: Lippincott Williams and Wilkins; 2005. p. 281-8.
de Falco FA, de Falco A, Striano P, Striano S, Santangelo R, Perretti A, et al. Benign adult familial myoclonic epilepsy: genetic heterogeneity and allelism with ADCME. Neurology. 2003;60(8):1381-5.
Striano P, Manganelli F, Boccella P, Perretti A, Striano S. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord. 2005;20(12):1610-4.
Kobayashi K, Hitomi T, Matsumoto R, Watanabe M, Takahashi R, Ikeda A. Nationwide survey in Japan endorsed diagnostic criteria of benign adult familial myoclonus epilepsy. Seizure. 2018;61:14-22.
Depienne C, Magnin E, Bouteiller D, Stevanin G, Saint-Martin C, Vidailhet M, et al. Familial cortical myoclonic tremor with epilepsy: the third locus (FCMTE3) maps to 5p. Neurology. 2010;74(24):2000-3.
Mahadevan R, Viswanathan N, Shanmugam G, Sankaralingam S, Essaki B, Chelladurai RP. Autosomal dominant cortical tremor, myoclonus, and epilepsy (ADCME) in a unique south Indian community. Epilepsia. 2016;57(3):e56-9.
Pena AB, Caviness JN. Physiology-based treatment of myoclonus. Neurotherapeutics. 2020;17(4):1665-80.
Guerrini R, Bonanni P, Patrignani A, Brown P, Parmeggiani L, Grosse P, et al. Autosomal dominant cortical myoclonus and epilepsy (ADCME) with complex partial and generalized seizures: a newly recognized epilepsy syndrome with linkage to chromosome 2p11.1-q12.2. Brain. 2001;124(Pt 12):2459-75.
Mir A, Alghamdi A, Alotaibi W, Samreen D, Alotaibi M, Albaradie R, et al. A systematic review of the efficacy of perampanel as treatment for myoclonic seizures and symptomatic myoclonus. Epileptic Disord. 2022;24(4):633-46.
Dubbioso R, Striano P, Tomasevic L, Bilo L, Esposito M, Manganelli F, et al. Abnormal sensorimotor cortex and thalamo-cortical networks in familial adult myoclonic epilepsy type 2: pathophysiology and diagnostic implications. Brain Commun. 2022;4(1):fcac037.
Oi K, Neshige S, Hitomi T, Kobayashi K, Tojima M, Matsuhashi M, et al. Low-dose perampanel improves refractory cortical myoclonus by the dispersed and suppressed paroxysmal depolarization shifts in the sensorimotor cortex. Clin Neurophysiol. 2019;130(10):1804-12.
Ueno T, Katagai A, Okudera R, Fujita M, Tomiyama M. Carbamazepine-induced convulsive status epilepticus in benign adult familial myoclonic epilepsy: a case report. Neurol Sci. 2022;44:377-9.
Striano P, Coppola A, Madia F, Pezzella M, Zara F, Striano S. Life-threatening status epilepticus following gabapentin administration in a patient with benign adult familial myoclonic epilepsy. Epilepsia. 2007;48(10):1995-8.
Nardone R, Versace V, Höller Y, Sebastianelli L, Brigo F, Lochner P, et al. Transcranial magnetic stimulation in myoclonus of different aetiologies. Brain Res Bull. 2018;140:258-69.
Houdayer E, Devanne H, Tyvaert L, Defebvre L, Derambure P, Cassim F. Low frequency repetitive transcranial magnetic stimulation over premotor cortex can improve cortical tremor. Clin Neurophysiol. 2007;118(7):1557-62.
Ishiura H, Doi K, Mitsui J, Yoshimura J, Matsukawa MK, Fujiyama A, et al. Expansions of intronic TTTCA and TTTTA repeats in benign adult familial myoclonic epilepsy. Nat Genet. 2018;50(4):581-90.
Wurster CD, Ludolph AC. Antisense oligonucleotides in neurological disorders. Ther Adv Neurol Disord. 2018;11:1756286418776932.
Corey DR. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nat Neurosci. 2017;20(4):497-9.
Coppola A, Caccavale C, Santulli L, Balestrini S, Cagnetti C, Licchetta L, et al. Psychiatric comorbidities in patients from seven families with autosomal dominant cortical tremor, myoclonus, and epilepsy. Epilepsy Behav. 2016;56:38-43.